98-31352. Findings of Scientific Misconduct  

  • [Federal Register Volume 63, Number 226 (Tuesday, November 24, 1998)]
    [Notices]
    [Pages 64966-64967]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-31352]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Office of the Secretary
    
    
    Findings of Scientific Misconduct
    
    AGENCY: Office of the Secretary, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: Notice is hereby given that the Office of Research Integrity 
    (ORI) has made a final finding of scientific misconduct in the 
    following case:
        Ms. Eileen Glennon, Harvard Medical School and Brigham and Women's 
    Hospital: Based on a report submitted to the Office of Research 
    Integrity (ORI) by the Harvard Medical School (HMS) on June 30, 1998, 
    as well as additional information obtained by ORI during its oversight 
    review, ORI found that Ms. Glennon, former research technician, 
    Endocrine-Hypertension Division, Brigham and Women's Hospital (BWH), 
    engaged in scientific misconduct arising out of certain biomedical 
    research supported by a grant from the National Heart, Lung, and Blood 
    Institute (NHLBI), National Institutes of Health (NIH), and a grant 
    from the National Center for Research Resources (NCRR), NIH.
        Specifically, Ms. Glennon fabricated data to plot standard curves 
    while conducting radioimmunoassays to determine angiotensin II 
    concentrations. When the assays appeared not to be working, which 
    occurred in approximately half of the assays over a one year period, 
    she used numbers from previous standard curves and then used the 
    fabricated standard curve to determine the concentration of angiotensin 
    II, thus producing false experimental results. Ms. Glennon cooperated 
    fully with the institutional inquiry panel and admitted her acts.
        Ms. Glennon has accepted the ORI finding and has entered into a 
    Voluntary Exclusion Agreement with ORI in which she has voluntarily 
    agreed, for the three (3) year period beginning November 13, 1998:
        (1) To exclude herself from serving in any advisory capacity to the 
    Public Health Service (PHS), including but not limited to service on 
    any PHS advisory committee, board, and/or peer review committee, or as 
    a consultant; and
        (2) That any institution that submits an application for PHS 
    support for a research project on which her participation is proposed 
    or which uses her in any capacity on PHS supported research, or that 
    submits a report of PHS-funded research in which she is involved, must 
    concurrently submit a plan for supervision of her duties to the
    
    [[Page 64967]]
    
    funding agency for approval. The supervisory plan must be designed to 
    ensure the scientific integrity of Ms. Glennon's research contribution. 
    The institution also must submit a copy of the supervisory plan to ORI.
    
    FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research 
    Investigations, Office of Research Integrity, 5515 Security Lane, Suite 
    700, Rockville, MD 20852, (301) 443-5330.
    Chris B. Pascal,
    Acting Director, Office of Research Integrity.
    [FR Doc. 98-31352 Filed 11-23-98; 8:45 am]
    BILLING CODE 4160-17-P
    
    
    

Document Information

Published:
11/24/1998
Department:
Health and Human Services Department
Entry Type:
Notice
Action:
Notice.
Document Number:
98-31352
Pages:
64966-64967 (2 pages)
PDF File:
98-31352.pdf